Arunalight and Wet AMD

Arunalight for Wet AMD

Clinical Safety & Use Statement – Patients Receiving Anti-VEGF Therapy

Arunalight® photobiomodulation (PBM) is not intended to treat neovascular (wet) age-related macular degeneration and does not replace anti-VEGF therapy. Anti-VEGF injections remain the standard of care and should be continued without delay or modification.

Clinical PBM trials, including LIGHTSITE III, evaluated PBM in non-neovascular (dry) AMD populations. PBM has not been established as a treatment for choroidal neovascularization, nor as an adjunct that alters anti-VEGF dosing requirements or outcomes.

There is currently no clinical evidence demonstrating that PBM interferes with anti-VEGF pharmacodynamics or increases injection-related adverse events. However, prospective safety data in eyes actively receiving anti-VEGF therapy are limited, and PBM use in this population should be considered supportive and discretionary.

If PBM is used in patients receiving injections, the following precautions are recommended:

• Arunalight® use in patients with active neovascular AMD should be under the supervision of a retinal specialist

• PBM should not be administered on injection days

• PBM sessions should be temporally separated from injections

• PBM should be discontinued if new exudative changes, hemorrhage, or unexplained visual decline occurs

• Ongoing retinal monitoring remains essential

Although scientific studies have shown promising results from PBM Red light therapy, results will vary by individual.  The goal of red light therapy is meant to help slow down the progression of Dry AMD Macular Degeneration, improvement of vision is not guaranteed.  The use of red light therapy at home as a wellness device DOES NOT replace routine examinations & treatments by your eye doctor plus the need for daily balanced nutrient-dense diet, outdoor light exposure, rest/exercise, & lifestyle changes.